LUNAPHORE PARTNERS WITH DISCOVERY LIFE SCIENCES TO BRING INNOVATIVE SPATIAL BIOLOGY SOLUTIONS TO CLINICAL RESEARCH
BIO-TECHNE TO PRESENT AT NEUROSCIENCE 2024-THE SOCIETY FOR NEUROSCIENCE (SfN) ANNUAL MEETING
Bio-Techne (NASDAQ:TECH) Stock Performs Better Than Its Underlying Earnings Growth Over Last Five Years
ScaleReady Announces a G-Rex Grant Has Been Awarded to ImmunoScape
Verismo Therapeutics Awarded a ScaleReady G-Rex Grant
Should You Investigate Bio-Techne Corporation (NASDAQ:TECH) At US$74.67?
ScaleReady and Bio-Techne Announce Optimal Closed System Cytokine Packaged for Single Step Use in Closed System G-Rex Manufacture of CAR-T and TCR Therapies
Express News | Bio-Techne Corp : RBC Raises Target Price to $77 From $70
Here's What Dragged Bio-Techne Corporation (TECH)?
Bio-Techne To Present At 2024 Wells Fargo Healthcare Conference; Webcast At 11:00 AM ET
BofA's Global Contenders and Defenders List
Some Investors May Be Willing To Look Past Bio-Techne's (NASDAQ:TECH) Soft Earnings
Baird Maintains Bio-Techne(TECH.US) With Buy Rating, Maintains Target Price $82
Baird analyst Catherine Ramsey Schulte maintains $Bio-Techne(TECH.US)$ with a buy rating, and maintains the target price at $82.According to TipRanks data, the analyst has a success rate of 56.0%
Optimistic Growth and Improved Financial Outlook for Bio-Techne: A Buy Recommendation
ScaleReady Announces the Inaugural G-Rex Grant Has Been Awarded to Stanford Medicine Laboratory for Cell and Gene Medicine
BIO-TECHNE TO PRESENT AT INVESTOR HEALTHCARE CONFERENCES
Estimating The Intrinsic Value Of Bio-Techne Corporation (NASDAQ:TECH)
Beyond the Balance Sheet: What SWOT Reveals About Bio-Techne Corp (TECH)
Bio-Techne | 10-K: FY2024 Annual Report
Is Wall Street Bullish or Bearish on Bio-Techne Stock?